Evidence map›Paper›PMID 26322287›Full record

ArticleAdvanced biomedical research2015

SIX1 overexpression in diffuse-type and grade III gastric tumors: Features that are associated with poor prognosis.

Modjtaba Emadi-Baygi, Parvaneh Nikpour, Elaheh Emadi-Andani

Open access · goldAbstract read
In one paragraph

Article in Advanced biomedical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer.Biochimica et biophysica acta. Reviews on cancer · 2024
    Review
  4. Introduction ofIranian journal of basic medical sciences · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Modjtaba Emadi-BaygiDepartment of Genetics, Research Institute of Biotechnology, Shahrekord University, Shahrekord, Iran.
Parvaneh NikpourDepartment of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran ; Pediatric Inherited Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran ; Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Elaheh Emadi-AndaniDepartment of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran.
Center for Inherited Blood Disorders · USIsfahan University of Medical Sciences · IRShahrekord University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer is the second most common cancer worldwide. In Iran, the incidence of gastric cancer is well above the world average, and is the first common cancer in Iranian men and the third one in women. Located at chromosome 14q23, SIX1 is a homolog of the Drosophila 'sine oculis' (so) gene and is highly conserved in numerous species. In addition to the role of SIX1 in the development, its expression is frequently dysregulated in multiple cancers. This study aimed to evaluate the clinicopathological features of the expression of SIX1 gene in gastric adenocarcinoma. MATERIALS AND

methodsThirty pairs of gastric tissue samples from patients with gastric adenocarcinoma were evaluated for SIX1 gene expression using quantitative real-time polymerase chain reaction. A paired t-test or one-way ANOVA with post hoc multiple comparisons were used to analyze the differences between groups. Statistical significance was defined as P ≤ 0.05.

resultsSIX1 expression was decreased in tumoral samples. However, its expression increased significantly in diffuse-type gastric cancer. Furthermore, there was a trend toward statistical significance in increasing SIX1 gene expression with higher grades. Of note, the difference was significant between grades I and III.

conclusionsThe results suggest that SIX1 gene expression might be used in the future as a potential biomarker to predict the outcome of the disease as diffuse-type and grade III of gastric tumors are associated with poor prognosis.

Indexed as

Diffuse-type gastric cancergene expressionpoor prognosis SIX1tumor grades

Identifiers

PMID26322287
PMCPMC4544127
OpenAlexW2225292540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.